NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$34.2b

Last Updated

2021/04/15 08:45 UTC

Data Sources

Company Financials

Executive Summary

Polaris Group provides consulting services to post-acute health care providers in the United States. More Details


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Polaris Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6550 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: 6550's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

-1.8%

6550

3.9%

TW Biotechs

0.2%

TW Market


1 Year Return

388.9%

6550

116.6%

TW Biotechs

61.6%

TW Market

Return vs Industry: 6550 exceeded the TW Biotechs industry which returned 116.6% over the past year.

Return vs Market: 6550 exceeded the TW Market which returned 61.6% over the past year.


Shareholder returns

6550IndustryMarket
7 Day-1.8%3.9%0.2%
30 Day55.8%17.3%4.2%
90 Day306.2%46.9%8.2%
1 Year388.9%388.9%117.6%116.6%67.1%61.6%
3 Year10.0%1.1%6.8%4.9%72.5%52.8%
5 Year17.3%3.2%-15.7%-17.7%136.5%94.5%

Long-Term Price Volatility Vs. Market

How volatile is Polaris Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Polaris Group undervalued compared to its fair value and its price relative to the market?

13.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6550's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6550's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6550 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6550 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6550's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6550 is overvalued based on its PB Ratio (15.6x) compared to the TW Biotechs industry average (5.4x).


Future Growth

How is Polaris Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

55.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Polaris Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Polaris Group performed over the past 5 years?

3.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6550 is currently unprofitable.

Growing Profit Margin: 6550 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6550 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.3% per year.

Accelerating Growth: Unable to compare 6550's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6550 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (80.8%).


Return on Equity

High ROE: 6550 has a negative Return on Equity (-23.68%), as it is currently unprofitable.


Financial Health

How is Polaris Group's financial position?


Financial Position Analysis

Short Term Liabilities: 6550's short term assets (NT$2.3B) exceed its short term liabilities (NT$242.3M).

Long Term Liabilities: 6550's short term assets (NT$2.3B) exceed its long term liabilities (NT$308.7M).


Debt to Equity History and Analysis

Debt Level: 6550's debt to equity ratio (7.9%) is considered satisfactory.

Reducing Debt: 6550's debt to equity ratio has increased from 1.7% to 7.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 6550 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 6550 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Polaris Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6550's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6550's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6550's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6550's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6550's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Polaris Group has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Polaris Group's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Polaris Group
  • Ticker: 6550
  • Exchange: GTSM
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$34.229b
  • Shares outstanding: 652.90m
  • Website: https://www.polaris-group.com

Location

  • Polaris Group
  • 3030 North Rocky Point Drive
  • Suite 240
  • Tampa
  • Florida
  • 33607
  • United States

Listings


Biography

Polaris Group provides consulting services to post-acute health care providers in the United States. The company offers consulting services and solutions, including medicare consulting, nursing consulting,...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/15 08:45
End of Day Share Price2021/04/14 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.